NTC and I-MED Pharma Partner to Bring HA-based Dry Eye Ointment to the United States Market

NTC Srl and I-MED Pharma announced today that I-Defense, a lubricating ointment containing 0.4% sodium hyaluronate indicated for the relief of dry eyes and lagophthalmos symptoms has been successfully registered with the FDA. It is the first European NTC medical device product for ophthalmic use approved in the United States. The viscous properties of I-Defense enable a prolonged contact-time with the ocular surface. This hydrating ointment provides soothing relief of dry eye symptoms and acts as a barrier against moisture loss.

“We are proud of our strategic partnership with a leading ophthalmic company such as I-Med Pharma,” in North America, Riccardo Carbucicchio, President and CEO of NTC, sais in a company news release. “We started our cooperation in Canada, and now we are excited that one of our innovative products for eye diseases will now become available to many patients in the U.S.A.” he adds.

Philipp Binder, President and Chief Operations Officer of I-MED Pharma commented, “We are excited about our collaboration with NTC to bring a leading HA-based ophthalmic ointment to the United States market. Both I-MED Pharma and NTC are equally committed to research and development within the ophthalmic space. We look forward to making this innovative dry eye ointment available exclusively through eye care professionals within the USA to help execute on our mission to bring complete relief to dry eye and ocular surface disease patients worldwide.”